Abbott Stock Is on Pace for Worst Day Since 2000. The Nutrition Business Is a Drag on Earnings.

Abbott Laboratories (ABT) is experiencing its most significant single-day stock decline in over two decades, as investor sentiment sours on its struggling nutrition segment. While the company's Medical Devices division, particularly the FreeStyle Libre product line, continues to show robust growth, the nutrition business remains plagued by market share recovery challenges and mounting legal pressures from lawsuits related to preterm infant formula. This divergence in performance is prompting a significant repricing of the stock by institutional investors. The decline suggests that the market is now more acutely factoring in the legal liabilities tied to necrotizing enterocolitis (NEC) lawsuits. Recent unfavorable jury verdicts against competitors and Abbott have highlighted the potential for substantial financial penalties. The company's historically defensive stock status is being challenged as investors grapple with the scale of these legal risks and the opaque timeline for resolution, which are eroding confidence despite stronger areas of the business. Moving forward, investors should closely monitor the outcomes of ongoing court cases and the company's ability to maintain its full-year financial guidance amidst these escalating legal expenses. The next major catalyst will be Abbott's third-quarter earnings report, where management's commentary on the nutrition segment's turnaround strategy and the quantification of legal provisions will be critical. The long-term investment thesis now hinges on whether the strong growth in medical devices can consistently offset the drag from the volatile and lower-margin nutrition business.